Nirsevimab reduced respiratory syncytial virus infections and hospitalisations in preterm infants in Phase IIb trial : AstraZeneca
India, July 31 -- Nirsevimab showed a significant reduction in medically-attended lower respiratory tract infections (LRTI) and hospitalisations caused by respiratory syncytial virus (RSV) in healthy preterm infants in a positive Phase IIb trial published in the New England Journal of Medicine.
The trial demonstrated for the first time that a single-dose monoclonal antibody (mAb) can significantly reduce medically-attended RSV LRTI, including bronchiolitis and pneumonia, in infants throughout the full RSV season.
On the primary endpoint, nirsevimab achieved a statistically significant 70.1% reduction in medically-attended RSV LRTI compared to placebo through 150 days post-dose.
On the secondary efficacy endpoint, nirsevimab achieved a ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.